BYDUREON BCISE
PeakNDASUBCUTANEOUSSUSPENSION, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYDUREON BCISE is a subcutaneous, extended-release suspension formulation approved by the FDA on October 20, 2017. The generic name and specific indication are not disclosed in available data, but the product is classified as a small-molecule NDA from AstraZeneca. Based on the BCISE formulation designation, this represents an improved delivery system for an established therapeutic agent. The product is currently in peak lifecycle stage, indicating strong market penetration and commercial maturity.
$0.3BPart D
4.9 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on BYDUREON BCISE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.